Targacept ADHD drug fails to meet primary endpoint
The primary endpoint of the trial was defined as change from baseline on the Conners’ Adult ADHD Rating Scale-Investigator Rated Total ADHD Symptoms score (CAARS-INV) after four, eight
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.
Disorazol Z is a bacterially produced compound with cytotoxic activity in the sub-nanomolar range. The proof-of-concept of LHRH-receptor targeting disorazol Z conjugates for the treatment of ovarian cancer